AbbVie Logs Another Phase III Success With Tavapadon In Parkinson’s
The firm said it will file the D1/D5 dopamine receptor agonist for US FDA approval in 2025. The drug may salvage value from AbbVie’s Cerevel buyout.
Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972
Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.
Spotlight On ASH
Interviews
Focus On Asia
What’s Driving Growing Optimism About India In Pharma Boardrooms
Eli Lilly’s India chief, at a recent summit, talks about India moving up the “priority list” when it comes to boardroom discussions, while the founding CEO, Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, outlines the implications for pharma as the massive publicly funded health assurance scheme widens coverage in the country.
Data Analysis
R&D
• By
The firm said it will file the D1/D5 dopamine receptor agonist for US FDA approval in 2025. The drug may salvage value from AbbVie’s Cerevel buyout.
• By
The company discontinued the Phase II STRIDES study testing azelaprag as monotherapy and in combination with Lilly’s tirzepatide in obesity.
• By
Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK’s oncology leader said he had never really doubted.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Business
• By
Eli Lilly’s India chief, at a recent summit, talks about India moving up the “priority list” when it comes to boardroom discussions, while the founding CEO, Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, outlines the implications for pharma as the massive publicly funded health assurance scheme widens coverage in the country.
• By
In this week's episode: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug.
• By
The Dutch group has assembled an impressive syndicate which is betting that the first-in-class monoclonal antibody CIT-013 could be a transformative treatment for rheumatoid arthritis and hidradenitis suppurativa.
• By
Plus deals involving Mitsubishi Tanabe/Dewpoint, Lilly/Rondo, Ono/Congruence, Bristol Myers Squibb/AI Proteins and more.
Scrip Originals
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
Plus deals involving Mitsubishi Tanabe/Dewpoint, Lilly/Rondo, Ono/Congruence, Bristol Myers Squibb/AI Proteins and more.
• By
Private Company Edition: Atlas Venture closed its $450m Fund XIV after some notable exits. Also, Nuvig’s $161m series B round more than triples its $47m series A from 2022, while Maze’s $115m series D fell below its prior $190m round and Antag raised an €80m ($84.7m) series A.
Recent moves in the industry include C-suite changes at Moderna, Valerio Therapeutics and Ocugen, plus IDEAYA Biosciences acquires chief commercial officer from Gilead Sciences.